Bausch & Lomb To Spur Lens Care Sales With New Solution Launch
This article was originally published in The Tan Sheet
Executive Summary
Bausch & Lomb plans to boost top line growth in its lens care category with the introduction of a new "first of its kind" lens solution next year
You may also be interested in...
Bausch & Lomb
U.S. Patent & Trademark Office grants Bausch & Lomb's patent for Ocuvite PreserVision antioxidant mineral formula Dec. 9. The same day, the Rochester, N.Y.-based company filed lawsuits in U.S. District Court against Alcon Labs, GNC, Leiner and Rexall Sundown, alleging that their respective eye vitamin products infringe on its patent rights. A study in the Archives of Ophthalmology November issue found that if, over the next five years, all those at risk of developing age-related macular degeneration took Ocuvite PreserVision, more than 300,000 people would avoid advanced ADM and any associated vision loss (1"The Tan Sheet" Nov. 17, 2003, p. 11). At a recent Bear Stearns conference, B&L CFO Steve McCloskey predicted the Ocuvite brand, which had around $50 mil. in sales in 2002, could reach $100 mil. to $200 mil. in the next few years (2"The Tan Sheet" Sept. 15, 2003, p. 6)...
NACDS In Brief
Leiner acetaminophen: Carson, Calif.-based firm now shipping private label gelatin-enrobed acetaminophen products comparable to McNeil's Tylenol, firm announces at National Association of Chain Drug Stores Marketplace in San Diego June 8-10. Shipments "will provide consumers with continued access to the same proven products they know and trust without any retail supply interruption," Leiner maintains. Firm noted it secured rights to manufacture Soflet enrobed pro-ducts last December after Banner Pharmacaps severed its relationship with Perrigo (1"The Tan Sheet" Feb. 3, 2003, p. 13). Soflets will be available in 10 delivery forms, including cold gelcap, sinus gelcap, PM gelcap, allergy sinus geltab...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC